- £66.51bn
- £79.57bn
- £30.33bn
- 87
- 48
- 95
- 91
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 9.57 | ||
| PEG Ratio (f) | 0.87 | ||
| EPS Growth (f) | 12.33% | ||
| Dividend Yield (f) | 3.88% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.81 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 12.56 | ||
| Price to Sales | 2.16 | ||
| EV to EBITDA | 9.52 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 15.91% | ||
| Return on Equity | 34.95% | ||
| Operating Margin | 20.02% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 33,754 | 24,354 | 24,696 | 29,324 | 30,328 | 31,722.79 | 33,734.69 | -0.32% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +58.64 | -53.46 | -13.66 | +67.65 | +22.91 | +13.83 | +10.78 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
Directors
- Jonathan Symonds NEC (62)
- Emma Walmsley CEO (52)
- Iain Mackay CFO (60)
- Roger Connor CEX
- Brian McNamara CEX
- Luke Miels CEX
- Regis Simard CEX
- Phil Thomson CEX
- Deborah Waterhouse CEX
- James Ford SVP
- Diana Conrad SVP
- Nick Hirons SVP
- Sally Jackson SVP (51)
- Karenann Terrell CTO (59)
- Hal Barron CSO (58)
- David Redfern OTH (55)
- Tony Wood OTH
- Victoria Whyte SEC
- Charles Bancroft NID (61)
- Marvinder Banga NID (66)
- Anne Beal NID
- Vivienne Cox NID
- Harry Dietz NID
- Lynn Elsenhans NID (64)
- Laurie Glimcher NID (70)
- Jesse Goodman NID (69)
- Judy Lewent NID (72)
- Urs Rohner NID (61)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- December 6th, 1999
- Public Since
- May 22nd, 1972
- No. of Shareholders
- 61,745
- No. of Employees
- 70,212
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
London Stock Exchange- Shares in Issue
- 4,144,963,782
- Address
- 980 Great West Road, BRENTFORD, TW8 9GS
- Web
- https://www.gsk.com/
- Phone
- +44 2080475000
- Auditors
- Deloitte LLP
Latest News for GSK
Upcoming Events for GSK
Q2 2024 GSK plc Earnings Release
Q3 2024 GSK plc Earnings Release
Similar to GSK
Alliance Pharma
London Stock Exchange
Animalcare
London Stock Exchange
Argent BioPharma
London Stock Exchange
AstraZeneca
London Stock Exchange
Beximco Pharmaceuticals
London Stock Exchange
FAQ
As of Today at 21:00 UTC, shares in GSK are trading at 1,604.50p. This share price information is delayed by 15 minutes.
Shares in GSK last closed at 1,604.50p and the price had moved by +16.71% over the past 365 days. In terms of relative price strength the GSK share price has outperformed the FTSE All Share Index by +9.6% over the past year.
The overall consensus recommendation for GSK is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The GSK dividend yield is 3.68% based on the trailing twelve month period.
Last year, GSK paid a total dividend of £0.59, and it currently has a trailing dividend yield of 3.68%.Looking ahead, the next dividend pay date is 2024-07-11.
We do not have data on when GSK is to next pay dividends. The historic dividend yield on GSK shares is currently 3.68%.
To buy shares in GSK you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 1,604.50p, shares in GSK had a market capitalisation of £66.51bn.
Here are the trading details for GSK:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: GSK
Based on an overall assessment of its quality, value and momentum GSK is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in GSK is 1,931.57p. That is 20.38% above the last closing price of 1,604.50p.
Analysts covering GSK currently have a consensus Earnings Per Share (EPS) forecast of £1.60 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like GSK. Over the past six months, its share price has outperformed the FTSE All Share Index by +5.99%.
As of the last closing price of 1,604.50p, shares in GSK were trading +2.34% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The GSK PE ratio based on its reported earnings over the past 12 months is 9.57. The shares last closed at 1,604.50p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
GSK's management team is headed by:
- Jonathan Symonds - NEC
- Emma Walmsley - CEO
- Iain Mackay - CFO
- Roger Connor - CEX
- Brian McNamara - CEX
- Luke Miels - CEX
- Regis Simard - CEX
- Phil Thomson - CEX
- Deborah Waterhouse - CEX
- James Ford - SVP
- Diana Conrad - SVP
- Nick Hirons - SVP
- Sally Jackson - SVP
- Karenann Terrell - CTO
- Hal Barron - CSO
- David Redfern - OTH
- Tony Wood - OTH
- Victoria Whyte - SEC
- Charles Bancroft - NID
- Marvinder Banga - NID
- Anne Beal - NID
- Vivienne Cox - NID
- Harry Dietz - NID
- Lynn Elsenhans - NID
- Laurie Glimcher - NID
- Jesse Goodman - NID
- Judy Lewent - NID
- Urs Rohner - NID